" class="no-js "lang="en-US"> SynAct Pharma Appoints Björn Westberg as CFO
Tuesday, April 23, 2024

SynAct Pharma Appoints Björn Westberg as Chief Financial Officer (CFO)

SynAct Pharma has announced that Björn Westberg has been appointed Chief Financial Officer (CFO) and member of the management team at SynAct. Björn has extensive experience from the life science sector, from smaller pharmaceutical companies to contract manufacturing and “Big Pharma”. He served as a CFO of several listed companies and most recently comes from his role as CFO at Attgeno.

Björn has more than 25 years of experience in the life science sector and has served as a chief financial officer since 2001. Prior to his role at privately held Attgeno, he was CFO at global cloud software company Enea, Swedish medtech Bonesupport, both of which are listed on Nasdaq Stockholm, and pharmaceutical developer and manufacturer Recipharm. He started his career at AstraZeneca where he worked in various capacities from 1989-2001.

“SynAct Pharma is at a critical point in its path to become a global leader in inflammatory diseases such as rheumatoid arthritis,” said Chairman Torbjørn Bjerke, who is set to become CEO on May 25. “The company is ready to take the next step forward, and we have a lot of work to do preparing our potential partners and shareholders for the next clinical results. We are pleased to have Björn join us as CFO and are confident his wealth of experience will be a welcome addition to the team as we work to execute on our growth plans.”

“I’m excited at the opportunity to join SynAct at such an important time in its development,” said CFO Björn Westberg. “The SynAct team has accomplished a lot over the past several years from joining the main list in Stockholm, gaining new investors and driving its development platform. I look forward to joining the team.”

Björn Westberg will take up the position full-time from August 16. He will formally start his position as CFO part-time on June 15, and replace Patrik Renblad who announced his resignation in February.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more